US Broker Ratings

Alcon Inc. (ALC) Stock Analysis: A 20% Upside Potential in the Healthcare Sector

Alcon Inc. (ALC), a stalwart in the healthcare sector, particularly in medical instruments and supplies, has been catching the attention of investors with its solid market presence and promising future..

BioNTech SE (BNTX) Stock Analysis: A Biotech Titan with 27% Potential Upside

BioNTech SE (NASDAQ: BNTX), a prominent player in the biotechnology sector, has been making waves in the healthcare industry with its innovative approach to developing immunotherapies for cancer and infectious..

Alnylam Pharmaceuticals (ALNY) Stock Analysis: High Growth Potential Amidst Expanding RNAi Pipeline

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leader in the biotechnology sector, has been at the forefront of discovering and commercializing therapeutics based on ribonucleic acid interference (RNAi). With a market..

BeOne Medicines Ltd. (ONC) Investor Outlook: 12.51% Potential Upside Amid Robust Revenue Growth

BeOne Medicines Ltd. (ONC), a prominent player in the biotechnology sector, is making waves with its focus on oncology treatments. Headquartered in Basel, Switzerland, the company is renowned for its..

Thermo Fisher Scientific (TMO) Stock Analysis: Navigating a 19% Potential Upside Amidst Strong Buy Ratings

Thermo Fisher Scientific Inc. (NYSE: TMO), a heavyweight in the healthcare sector, continues to capture investor interest with its robust market presence and strategic developments. With a current market capitalization..

Elevance Health, Inc. (ELV) Stock Analysis: A Strategic Look at its 35.56% Potential Upside

Elevance Health, Inc. (NYSE: ELV), a prominent player in the healthcare plans sector, is capturing investor attention with a considerable potential upside of 35.56%. As healthcare remains a crucial focus..

CVS Health Corporation (CVS) Stock Analysis: A 27.91% Upside Potential Amid Strong Buy Ratings

Investors looking for stability and growth in the healthcare sector might find CVS Health Corporation (NYSE: CVS) a promising option. With a market capitalization of $79.23 billion, CVS is a..

Centene Corporation (CNC) Stock Analysis: Exploring a 37.50% Potential Upside in the Healthcare Sector

Centene Corporation (NYSE: CNC) stands as a formidable player in the U.S. healthcare sector, specializing in healthcare plans and services that cater to under-insured and uninsured families, as well as..

GE HealthCare Technologies Inc. (GEHC) Stock Analysis: Navigating a 26% Potential Upside in the Healthcare Sector

For investors eyeing opportunities in the healthcare sector, GE HealthCare Technologies Inc. (NYSE: GEHC) presents a compelling narrative. With a market capitalization of $31.89 billion, this Chicago-based company stands strong..

Johnson & Johnson (JNJ) Stock Analysis: Evaluating a 4.54% Growth Potential in the Healthcare Giant

Johnson & Johnson (NYSE: JNJ), a stalwart in the healthcare sector, continues to capture the interest of investors with its robust market presence and potential for growth. With a market..

HCA Healthcare, Inc. (HCA) Stock Analysis: Exploring a 10.27% Upside Potential and Robust Growth Metrics

As one of the leading entities in the U.S. medical care facilities industry, HCA Healthcare, Inc. (NYSE: HCA) presents a compelling investment opportunity. With a market capitalization of $85.88 billion,..

AbbVie Inc. (ABBV) Stock Analysis: Evaluating Growth Potential with a 9.17% Upside

AbbVie Inc. (NYSE: ABBV), a powerhouse in the healthcare sector, continues to capture investor attention with its robust pipeline of biopharmaceutical innovations. With a commanding market capitalization of $344.84 billion,..

Becton, Dickinson (BDX) Stock Analysis: A Compelling 18% Upside Potential for Healthcare Investors

Becton, Dickinson and Company (NYSE: BDX), a stalwart in the healthcare sector, stands out with a market capitalization of $50.55 billion. As a leader in medical instruments and supplies, BDX..

Takeda Pharmaceutical Company L (TAK) Investor Outlook: A 19.39% Potential Upside Despite Revenue Challenges

Takeda Pharmaceutical Company Limited (NYSE: TAK), a stalwart in the global healthcare sector, may catch the discerning eye of investors searching for value in the pharmaceutical industry. With a market..

GSK plc (GSK) Stock Analysis: Exploring Its 4.39% Dividend Yield and Growth Potential

For investors with a keen eye on the healthcare sector, GSK plc (NYSE: GSK) presents an intriguing opportunity. As one of the leading players in the drug manufacturing industry, GSK..

Zoetis Inc. (ZTS) Investor Outlook: Exploring a 31% Upside Potential in the Animal Health Leader

Zoetis Inc. (NYSE: ZTS) stands as a titan in the realm of animal health, commanding a market capitalization of $65.61 billion. As a key player in the healthcare sector, particularly..

Medtronic plc (MDT) Stock Analysis: Exploring a 8.15% Potential Upside in the Medical Device Sector

Medtronic plc (MDT), a titan in the healthcare sector, is a prominent player in the medical devices industry. Headquartered in Galway, Ireland, Medtronic has a robust market capitalization of $114.47..

Danaher Corporation (DHR) Stock Analysis: A 25% Upside Beckons Investors Amid Solid Buy Ratings

Danaher Corporation (NYSE: DHR), a titan in the healthcare sector, particularly within the diagnostics and research industry, has captured the attention of investors with a robust market cap of $141.13..

Stryker Corporation (SYK) Investor Outlook: Analyzing the 14.22% Potential Upside Amid Robust Revenue Growth

Stryker Corporation (NYSE: SYK) stands out in the healthcare sector as a formidable player in the medical devices industry. With a market capitalization of $144.43 billion, Stryker not only attests..

Intuitive Surgical, Inc. (ISRG) Stock Analysis: Exploring a 20.81% Potential Upside in the Healthcare Innovator

Intuitive Surgical, Inc. (NASDAQ: ISRG) stands as a titan in the healthcare industry, with a market capitalization of $173.19 billion. Specializing in medical instruments and supplies, this California-based company is..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds